About Mendel.ai
Mendel.ai enhances clinical data analysis in healthcare, specifically in oncology research and clinical trials, by using artificial intelligence to analyze large datasets like electronic medical records and genetic information. This technology helps identify suitable cancer patients for clinical trials more efficiently than traditional methods. The company serves researchers, clinicians, and pharmaceutical companies with a subscription-based model, offering access to its AI tools and customized solutions. Mendel.ai's goal is to improve the efficiency and accuracy of clinical trials, ultimately leading to better patient outcomes.
San Jose, CaliforniaHeadquarters
2017Year Founded
$63.6MTotal Funding
SERIES_BCompany Stage
Enterprise Software, AI & Machine Learning, HealthcareIndustries
51-200Employees
Benefits
Remote Work Options
Professional Development Budget
Flexible Work Hours
Risks
Generative AI's data 'hallucinations' could harm Mendel.ai's credibility in clinical settings.
Competition from companies adopting Meta's Llama 3 NIM may affect market share.
Challenges in drug trial success rates could impact client satisfaction with Mendel.ai.
Differentiation
Mendel.ai uses neuro-symbolic AI to address generative AI limitations in healthcare.
The Hypercube platform integrates with Snowflake and Azure for scalable data analysis.
Mendel.ai's AI tools focus on oncology, enhancing clinical trial patient matching.
Upsides
Partnerships with Google Cloud and Microsoft Azure expand Mendel.ai's customer base.
The AI in clinical trials market is projected to grow significantly by 2035.
Rising demand for RWE and RWD offers Mendel.ai opportunities to improve patient outcomes.
Funding
Total raised$63.62 M
Latest valuation$200.00 M
StageSERIES_B
SERIES B
3/31/2022$40
$200.00 MSEED
10/31/2019$3
$15.00 M